GlassScriptPhysician profile
Aimee Beth Levinson
NPI 1447928411
$5,111.85
in general payments reported to CMS, 2019-2025
28 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $1,897 · 2023: $669 · 2024: $954 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.12 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $883.85 | 2022 | |
| Daiichi Sankyo INC. | $558.21 | 2022-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $532.71 | 2023-2025 | Myfembree, Gemtesa, Orgovyx |
| Mayne Pharma Commercial LLC | $382.90 | 2022-2025 | |
| Intuitive Surgical, INC. | $305.38 | 2021-2023 | Davinci Xi |
| Astellas Pharma US INC | $301.06 | 2022-2025 | Veozah |
| Biogen, INC. | $254.38 | 2024-2025 | Zurzuvae |
| Axonics, INC. | $250.96 | 2022-2024 | Axonics |
| Organon LLC | $199.00 | 2022-2023 | Nexplanon |
| Coopersurgical, INC. | $157.68 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $142.18 | 2022-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Myovant Sciences INC. | $134.18 | 2022 | |
| Boston Scientific Corporation | $133.38 | 2025 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $120.50 | 2023-2025 | |
| Novo Nordisk INC | $114.97 | 2024 | Wegovy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $111.77 | 2023-2024 | |
| Evofem Biosciences, INC. | $106.99 | 2024-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $76.51 | 2022-2024 | Slynd |
| Convatec INC. | $52.59 | 2025 | |
| Therapeuticsmd, INC. | $48.91 | 2022 | |
| Millicent US INC | $42.90 | 2025 | Intrarosa, Femlyv |
| Becton, Dickinson and Company | $42.35 | 2021 | |
| Aspira Women'S Health INC | $39.20 | 2022-2024 | Ova1 |
| Pfizer INC. | $38.26 | 2023 | |
| Medtronic, INC. | $30.05 | 2023-2025 | Nuro |
| Octapharma USA, INC. | $21.70 | 2025 | Fibryga |
| Mycovia Pharmaceuticals, INC. | $15.58 | 2022 | |
| Olympus America INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.